A phase II study of Ampligen (rintatolimod) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Trial Profile

A phase II study of Ampligen (rintatolimod) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Chronic fatigue syndrome; Encephalomyelitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2016 According to a Hemispherx Biopharma media release, based on the date from this and other studies the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) approved Rintatolimod in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
    • 17 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top